Characterization of biased airway smooth muscle TAS2R agonists for treating asthma

偏向气道平滑肌 TAS2R 激动剂治疗哮喘的表征

基本信息

  • 批准号:
    10322110
  • 负责人:
  • 金额:
    $ 54.16万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-01-01 至 2024-12-31
  • 项目状态:
    已结题

项目摘要

Asthma remains a major public health issue worldwide, affecting all ages and ethnicities, with 50% of patients experiencing inadequate control of the disease. Constricted airways from contraction of airway smooth muscle is the major cause of airflow obstruction, and morbidity and mortality, in asthma. Despite this key point for intervention, only one class of direct bronchodilators (-agonists) are available for treatment, and they are suboptimal for many patients. We have discovered bitter taste receptors (TAS2Rs) on human airway smooth muscle (HASM) cells which signal by a unique mechanism. When activated, TAS2Rs markedly relax HASM and relieve airway obstruction that is otherwise resistant to -agonists. However, the known TAS2R agonists have low affinity and evoke desensitization (tachyphylaxis) of the relaxation response over time via -arrestin mechanisms. The overarching hypothesis is that TAS2R agonists with novel structures can be highly effective in relaxing airways in an asthmatic milieu and yet not evoke tachyphylaxis. The broad long-term objectives are to determine the 3D structures and binding sites of two TAS2Rs expressed on HASM (R5 and R14) and then use these structures to perform virtual docking of an agnostic ultra-large compound library to identify potential ligands. These hits will be examined in engineered model cells, but will be most intensely studied within the context of the physiology of HASM cells, and human airways, under asthmatic conditions to delineate novel ways to engage the receptor that are biased towards relaxation and away from desensitization. Aim 1 will computationally determine the structures and binding sites for R5 and R14 using methods that include 13 trillion combinations of the residues to determine favorable energy conformations of inactive and active states. The structures will be used to dock compounds from a highly diverse library. These will be studied in Aim 2 to determine potency and efficacy in genetically engineered model cells and in HASM cells from nonasthmatic and asthmatic lungs. In Aim 3, the most favorable compounds will be studied to ascertain -arrestin engagement and biasing away from desensitization in model cells, HASM cells, and human lungs under asthmatic conditions. Results from Aims2/3 will be fed back into Aim1 to further refine a model of biased agonists for these HASM TAS2Rs. Based on our preliminary data that support all three Aims, we will learn about the structural requirements for biasing for these receptors. And, we anticipate that multiple highly effective agonists with unexpected structures will be identified and that their bronchodilating properties in asthma will represent a new class of powerful non-desensitizing agents for treating and preventing bronchospasm.
哮喘仍然是世界范围内的一个主要公共卫生问题,影响到所有年龄和种族,50%的患者 感受到对疾病控制不力。气道平滑肌收缩所致的气道收缩 是导致哮喘气流阻塞、发病率和死亡率的主要原因。尽管这一点对 干预,只有一类直接支气管扩张剂(激动剂)可用于治疗,它们是 对许多患者来说不是最理想的。我们在人的呼吸道上发现了苦味受体(TAS2Rs) 肌肉(HASM)细胞通过一种独特的机制发出信号。当被激活时,TAS2Rs显著放松HASM和 缓解对激动剂有抵抗力的呼吸道阻塞。然而,已知的TAS2R激动剂已经 低亲和力和通过-arrestin引起的随时间的松弛反应的脱敏(快速反应) 机制。最重要的假设是,具有新结构的TAS2R激动剂可以非常有效 在哮喘环境中放松呼吸道,但不会引起心动过速。宏大的长期目标是 确定HASM上表达的两个TAS2Rs(R5和R14)的三维结构和结合位点 使用这些结构来执行不可知的超大型化合物库的虚拟对接,以确定潜在的 配基。这些命中结果将在工程模型细胞中进行检查,但将在 哮喘条件下HASM细胞和人类呼吸道的生理学背景,以描绘新的途径 使偏向松弛而不是脱敏的受体参与。目标1将 使用包括13万亿的方法计算确定R5和R14的结构和结合位点 残基的组合以确定非活化态和活化态的有利能量构象。这个 结构将被用来对接来自高度多样化的图书馆的化合物。这些将在目标2中进行研究 确定基因工程模型细胞和非哮喘和非哮喘HASM细胞的效力和疗效 哮喘的肺。在目标3中,将研究最有利的化合物以确定-arrestin结合 以及在哮喘条件下的模型细胞、HASM细胞和人肺中偏向脱敏。 Aims2/3的结果将反馈给Aim1,以进一步提炼这些HASM的偏向激动剂模型 TAS2Rs。根据我们支持这三个目标的初步数据,我们将了解结构 对这些受体的偏置要求。而且,我们预计多种高效的激动剂 意想不到的结构将被识别,它们在哮喘中的支气管扩张特性将代表一种新的 治疗和预防支气管痉挛的一类有效的非脱敏药物。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Stephen B Liggett其他文献

Stephen B Liggett的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Stephen B Liggett', 18)}}的其他基金

Characterization of biased airway smooth muscle TAS2R agonists for treating asthma
偏向气道平滑肌 TAS2R 激动剂治疗哮喘的表征
  • 批准号:
    10543121
  • 财政年份:
    2021
  • 资助金额:
    $ 54.16万
  • 项目类别:
Molecular properties of B-adrenergic receptors in Asthma
哮喘中 B-肾上腺素能受体的分子特性
  • 批准号:
    9130410
  • 财政年份:
    2015
  • 资助金额:
    $ 54.16万
  • 项目类别:
Project 2 - Airway Smooth Muscle Bitter Taste Receptors as Targets for Novel Bronchodilators
项目 2 - 气道平滑肌苦味受体作为新型支气管扩张剂的靶标
  • 批准号:
    10465061
  • 财政年份:
    2013
  • 资助金额:
    $ 54.16万
  • 项目类别:
Project 2 - Airway Smooth Muscle Bitter Taste Receptors as Targets for Novel Bronchodilators
项目 2 - 气道平滑肌苦味受体作为新型支气管扩张剂的靶点
  • 批准号:
    10683126
  • 财政年份:
    2013
  • 资助金额:
    $ 54.16万
  • 项目类别:
Project 2 - Airway Smooth Muscle Bitter Taste Receptors as Targets for Novel Bronchodilators
项目 2 - 气道平滑肌苦味受体作为新型支气管扩张剂的靶标
  • 批准号:
    10238021
  • 财政年份:
    2013
  • 资助金额:
    $ 54.16万
  • 项目类别:
Lung HRV: G-Protein Coupled Signaling Interactions in Asthma
肺 HRV:哮喘中 G 蛋白耦合信号传导相互作用
  • 批准号:
    7783557
  • 财政年份:
    2010
  • 资助金额:
    $ 54.16万
  • 项目类别:
Lung HRV: G-Protein Coupled Signaling Interactions in Asthma
肺 HRV:哮喘中 G 蛋白耦合信号传导相互作用
  • 批准号:
    8403707
  • 财政年份:
    2010
  • 资助金额:
    $ 54.16万
  • 项目类别:
Lung HRV: G-Protein Coupled Signaling Interactions in Asthma
肺 HRV:哮喘中 G 蛋白耦合信号传导相互作用
  • 批准号:
    8197661
  • 财政年份:
    2010
  • 资助金额:
    $ 54.16万
  • 项目类别:
Lung HRV: G-Protein Coupled Signaling Interactions in Asthma
肺 HRV:哮喘中 G 蛋白耦合信号传导相互作用
  • 批准号:
    8010837
  • 财政年份:
    2010
  • 资助金额:
    $ 54.16万
  • 项目类别:
Lung HRV: G-Protein Coupled Signaling Interactions in Asthma
肺 HRV:哮喘中 G 蛋白耦合信号传导相互作用
  • 批准号:
    8544624
  • 财政年份:
    2010
  • 资助金额:
    $ 54.16万
  • 项目类别:

相似海外基金

Construction of affinity sensors using high-speed oscillation of nanomaterials
利用纳米材料高速振荡构建亲和传感器
  • 批准号:
    23H01982
  • 财政年份:
    2023
  • 资助金额:
    $ 54.16万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Affinity evaluation for development of polymer nanocomposites with high thermal conductivity and interfacial molecular design
高导热率聚合物纳米复合材料开发和界面分子设计的亲和力评估
  • 批准号:
    23KJ0116
  • 财政年份:
    2023
  • 资助金额:
    $ 54.16万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Development of High-Affinity and Selective Ligands as a Pharmacological Tool for the Dopamine D4 Receptor (D4R) Subtype Variants
开发高亲和力和选择性配体作为多巴胺 D4 受体 (D4R) 亚型变体的药理学工具
  • 批准号:
    10682794
  • 财政年份:
    2023
  • 资助金额:
    $ 54.16万
  • 项目类别:
Platform for the High Throughput Generation and Validation of Affinity Reagents
用于高通量生成和亲和试剂验证的平台
  • 批准号:
    10598276
  • 财政年份:
    2023
  • 资助金额:
    $ 54.16万
  • 项目类别:
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
  • 批准号:
    2233343
  • 财政年份:
    2023
  • 资助金额:
    $ 54.16万
  • 项目类别:
    Standard Grant
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
  • 批准号:
    2233342
  • 财政年份:
    2023
  • 资助金额:
    $ 54.16万
  • 项目类别:
    Standard Grant
Molecular mechanisms underlying high-affinity and isotype switched antibody responses
高亲和力和同种型转换抗体反应的分子机制
  • 批准号:
    479363
  • 财政年份:
    2023
  • 资助金额:
    $ 54.16万
  • 项目类别:
    Operating Grants
Deconstructed T cell antigen recognition: Separation of affinity from bond lifetime
解构 T 细胞抗原识别:亲和力与键寿命的分离
  • 批准号:
    10681989
  • 财政年份:
    2023
  • 资助金额:
    $ 54.16万
  • 项目类别:
CAREER: Engineered Affinity-Based Biomaterials for Harnessing the Stem Cell Secretome
职业:基于亲和力的工程生物材料用于利用干细胞分泌组
  • 批准号:
    2237240
  • 财政年份:
    2023
  • 资助金额:
    $ 54.16万
  • 项目类别:
    Continuing Grant
ADVANCE Partnership: Leveraging Intersectionality and Engineering Affinity groups in Industrial Engineering and Operations Research (LINEAGE)
ADVANCE 合作伙伴关系:利用工业工程和运筹学 (LINEAGE) 领域的交叉性和工程亲和力团体
  • 批准号:
    2305592
  • 财政年份:
    2023
  • 资助金额:
    $ 54.16万
  • 项目类别:
    Continuing Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了